###begin article-title 0
A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease
###end article-title 0
###begin p 1
###xml 95 123 95 123 <email xmlns:xlink="http://www.w3.org/1999/xlink">mnashimoto@niigatayakudai.jp</email>
To whom correspondence should be addressed. Tel: +81 250 25 5119; Fax: +81 250 25 5021; Email: mnashimoto@niigatayakudai.jp
###end p 1
###begin p 2
###xml 353 358 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 432 437 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 478 494 466 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 551 554 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 720 723 708 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 803 808 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 877 882 865 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 184 187 <span type="species:ncbi:9823">pig</span>
###xml 310 315 <span type="species:ncbi:9606">human</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 478 494 <span type="species:ncbi:562">Escherichia coli</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:4932">yeast</span>
###xml 663 668 <span type="species:ncbi:9606">human</span>
###xml 775 780 <span type="species:ncbi:9606">human</span>
###xml 899 904 <span type="species:ncbi:9606">human</span>
tRNA 3' processing endoribonuclease (3' tRNase) is an enzyme responsible for the removal of a 3' trailer from precursor tRNA (pre-tRNA). We purified approximately85 kDa 3' tRNase from pig liver and determined its partial sequences. BLAST search of them suggested that the enzyme was the product of a candidate human prostate cancer susceptibility gene, ELAC2, the biological function of which was totally unknown. We cloned a human ELAC2 cDNA and expressed the ELAC2 protein in Escherichia coli. The recombinant ELAC2 was able to cleave human pre-tRNAArg efficiently. The 3' tRNase activity of the yeast ortholog YKR079C was also observed. The C-terminal half of human ELAC2 was able to remove a 3' trailer from pre-tRNAArg, while the N-terminal half failed to do so. In the human genome exists a gene, ELAC1, which seems to correspond to the C-terminal half of 3' tRNase from ELAC2. We showed that human ELAC1 also has 3'-tRNase activity. Furthermore, we examined eight ELAC2 variants that seem to be associated with the occurrence of prostate cancer for 3'-tRNase activity. Seven ELAC2 variants which contain one to three amino acid substitutions showed efficient 3'-tRNase activities, while one truncated variant, which lacked a C-terminal half region, had no activity.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c3">3</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c4">4</xref>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c6">6</xref>
###xml 639 644 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 708 709 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 710 711 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c7">7</xref>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c8">8</xref>
###xml 1150 1155 1150 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 766 771 <span type="species:ncbi:9606">human</span>
Prostate cancer is a complex disorder that is caused by a multitude of genetic and environmental factors. Recently, a candidate prostate cancer susceptibility gene, ELAC2, has been identified at chromosome 17p by positional cloning and mutation screening (1). An insertion/frameshift mutation and a non-conservative missense mutation in ELAC2 segregate with prostate cancer in two kindreds (1). Several studies report that two common missense variants in the gene are also significantly associated with the occurrence of prostate cancer (1-3), although several groups argue against this association (4-6). Sequence analysis suggested that ELAC2 encodes an evolutionally conserved, metal-dependent hydrolase (1,7), which could partly explain environmental effects on human prostate cells by imagining differential interaction of the enzyme variants with some environmental exposure (1). In addition, the gene product showed similarity to a family of DNA interstrand crosslink repair proteins (8), which seemed consistent with a potential role in cancer susceptibility. Despite the fundamental biological interest, however, the genuine function of the ELAC2 product was totally unknown. Here we demonstrate experimentally that the prostate cancer susceptibility gene encodes an unfamiliar but important enzyme which is essential for tRNA biosynthesis, that is, tRNA 3' processing endoribonuclease (3' tRNase).
###end p 4
###begin p 5
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c9">9</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c10">10</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c11">11</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c11">11</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c14">14</xref>
###xml 486 494 486 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c14">14</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c11">11</xref>
3' tRNase is an enzyme responsible for the removal of a 3' trailer from precursor tRNA (pre-tRNA) which is transcribed as a larger form (9). The enzyme cleaves pre-tRNA immediately downstream of a discriminator nucleotide (10,11), onto which the CCA residues are added to produce mature tRNA. We have shown that mammalian 3' tRNase can remove 3' trailers from various pre-tRNAs with various efficiencies (11-14). Pre-tRNA 5' leaders affect the efficiency of tRNA 3' processing reaction in vitro; leaders of 9 nt or longer severely inhibit the tRNA 3' processing reaction, and even small 5' leaders, when stably base-paired with 3' trailers, hinder removal of the 3' trailers by 3' tRNase (14). Besides the 5' leaders, the 3' trailers also affect the cleavage efficiency of pre-tRNAs, which varies depending on both the length and the 5' end nucleotide of the 3' trailer (11).
###end p 5
###begin p 6
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c15">15</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c17">17</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c10">10</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c18">18</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c20">20</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c21">21</xref>
Mammalian 3' tRNase is unique in that a relatively stable complex between the enzyme and a 3'-truncated tRNA can function as a four-base-recognizing RNA cutter (RNase 65) (15-17). Although little is known about the physiological role and substrate of RNase 65, it has been demonstrated that the 3'-truncated tRNA directs substrate specificity via four base-pairings (10). Another unique point is that mammalian 3' tRNase possesses a property of being able to cleave any RNA at any site under the direction of small guide RNA (18-20) like an RNA-induced silencing complex (RISC) underlying RNA interference (21).
###end p 6
###begin p 7
In addition to these studies focusing on 3'-tRNase interactions with various pre-tRNAs and pre-tRNA-like complexes, we had also been making efforts towards cloning a 3'-tRNase cDNA, and finally came across the prostate cancer susceptibility gene.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Enzyme purification and microsequencing
###end title 9
###begin p 10
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c10">10</xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 0 3 <span type="species:ncbi:9823">Pig</span>
Pig 3' tRNase was intensively fractionated from liver basically as described before (10), and further purified by glycerol gradient ultracentrifugation. We layered the 3'-tRNase fractions after Mono Q column chromatography onto a 10 ml 15-30% glycerol gradient in a buffer (20 mM Tris-HCl, pH 7.5, 0.2 mM EDTA), and centrifuged them at 100 000 g for 48 h at 4degreesC. The final active fraction was separated on an SDS-10% polyacrylamide gel. A protein band was visualized by staining the gel with Coomassie brilliant blue R-250.
###end p 10
###begin p 11
We excised a gel strip containing the protein band, and subjected the protein to trypsin digestion and analyzed resulting peptides with a mass spectrometer. The microsequencing was carried out by Protana (Odense, Denmark).
###end p 11
###begin title 12
Cloning of 3'-tRNase cDNAs
###end title 12
###begin p 13
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sap</italic>
###xml 200 203 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 218 234 218 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c22">22</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c23">23</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 218 234 <span type="species:ncbi:562">Escherichia coli</span>
The complete protein coding region (2478 bp) of a human ELAC2 cDNA was PCR-amplified with LA Taq DNA polymerase (Takara Shuzo) from a human testis cDNA library (Clontech), and cloned between SapI and XhoI sites of the Escherichia coli expression vector pTYB11 (New England BioLabs). The two primer pairs 5'-GACAAGCTCTTCCAACATGTGGGCGCTTTGCTCG-3'/5'-ACACAGTTCTTCAGCCAA-3' and 5'-TTGGCTGAAGAACTGTGT-3'/5'-CCGCTCGAGTTACTGGGCTCTGACCTTCT-3' were used. Because the obtained cDNA contained several base substitutions that change amino acids, we repaired them by PCR using appropriate primer sets with Pyrobest DNA polymerase (Takara Shuzo) that has a proof-reading activity (22,23). We confirmed that the sequence of the ELAC2 coding region of the resultant plasmid pTYB11/ELAC2 is the same as the sequence previously published (GenBank accession no. AF304370), using a CEQ Dye Terminator Cycle Sequencing Kit (Bechman Coulter).
###end p 13
###begin p 14
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 189 213 189 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 445 452 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 516 519 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 526 529 526 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 598 605 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 631 634 631 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 93 98 <span type="species:ncbi:4932">yeast</span>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 189 213 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
In a similar fashion, the full-length coding regions of a human ELAC1 cDNA (1089 bp) and the yeast YKR079C gene (2514 bp) were PCR-amplified from the human testis cDNA library and from the Saccharomyces cerevisiae genome, respectively. The primer pairs 5'-CGGGATCCATGTCTATGGATGTGACA-3'/5'-CCGCTCGAGTTATTTCTTGATTGGAATGC-3' and 5'-GGAATTCCATGTTCACATT TATACCCATC-3'/5'-GGAATTCTTAATTTTTCTTGTGTTTCTTAA-3' were used for the amplification of ELAC1 and YKR079C, respectively. The amplified ELAC1 cDNA was cloned between the BamHI and XhoI sites of pGEX-4T-3 (Amersham Pharmacia Biotech), and the amplified YKR079C gene was cloned into the EcoRI site of pGEX-4T-3. After corrections of PCR errors as above, we confirmed that the insert regions of pGEX-4T-3/ELAC1 and pGEX-4T-3/YKR079C are the same as the sequences previously published (GenBank accession nos AF308695 and Z28304, respectively).
###end p 14
###begin title 15
Construction of expression plasmids for 3'-tRNase variants
###end title 15
###begin p 16
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 264 273 256 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu</sup>
###xml 334 343 326 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ala541Thr</sup>
###xml 404 413 396 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg781His</sup>
###xml 474 493 466 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu/Ala541Thr</sup>
###xml 566 585 558 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ala541Thr/Arg781His</sup>
###xml 658 677 650 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg781His/Ser217Leu</sup>
###xml 750 779 742 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu/Ala541Thr/Arg781His</sup>
###xml 867 875 859 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1641insG</sup>
###xml 1091 1093 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c22">22</xref>
###xml 1094 1096 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c23">23</xref>
###xml 74 80 <span type="species:ncbi:562">E.coli</span>
Based upon pTYB11/ELAC2, we constructed its ten derivatives to express in E.coli 10 different 3'-tRNase variants: pTYB11/ELAC2-DeltaC for the N-terminal half ELAC2 (residues 1-480), pTYB11/ELAC2-DeltaN for the C-terminal half ELAC2 (residues 482-826), pTYB11/ELAC2Ser217Leu for ELAC2 con taining a Ser217Leu substitution, pTYB11/ELAC2Ala541Thr for ELAC2 containing an Ala541Thr substitution, pTYB11/ELAC2Arg781His for ELAC2 containing an Arg781His substitution, pTYB11/ELAC2Ser217Leu/Ala541Thr for ELAC2 containing Ser217Leu and Ala541Thr substitutions, pTYB11/ELAC2Ala541Thr/Arg781His for ELAC2 containing Ala541Thr and Arg781His substitutions, pTYB11/ELAC2Arg781His/Ser217Leu for ELAC2 containing Arg781His and Ser217Leu substitutions, pTYB11/ELAC2Ser217Leu/Ala541Thr/Arg781His for ELAC2 containing Ser217Leu, Ala541Thr and Arg781His substitutions, and pTYB11/ELAC21641insG for ELAC2 containing the C-terminal truncation due to the G-insersion/frameshift change at nucleotide 1641. These pTYB11/ELAC2 derivatives were generated by site-directed mutagenesis by overlap extension using PCR (22,23) and/or by the conventional DNA recombination technique with DNA restriction enzymes and DNA ligase. We confirmed that the insert sequences are changed correctly by DNA sequencing as above.
###end p 16
###begin title 17
Expression and purification of recombinant proteins encoded in the pTYB11 constructs
###end title 17
###begin p 18
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c22">22</xref>
###xml 62 68 <span type="species:ncbi:562">E.coli</span>
The recombinant ELAC2 and its variants were over-expressed in E.coli and purified with chitin beads as described previously (22). The expressed proteins were identified by liquid chromatographic mass spectrometry (LC/MS/MS) analyses with the ion trap mass spectrometer LCQ Advantage (Thermo Finnigan) equipped with an electrospray ionization source and the high performance liquid chromatography system MAGIC 2002 (Michrom BioResources).
###end p 18
###begin title 19
Expression and purification of GST fusion proteins
###end title 19
###begin p 20
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 194 195 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 195 198 181 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600</sub>
###xml 655 656 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 0 16 <span type="species:ncbi:562">Escherichia coli</span>
Escherichia coli strain DH5alpha that harbors the expression plasmid for GST-YKR079C or GST-ELAC1 was incubated at 37degreesC in 250 ml of LB medium containing 50 microg/ml ampicillin until the A600 of the culture reached 0.6. At this point, the fusion protein was induced by adding IPTG (500 microM). After further incubation at 37degreesC for 4 h, the cells were harvested by centrifugation. Cell pellets were resuspended in 10 ml of lysis buffer (50 mM Tris-HCl, pH 7.6, 500 mM NaCl, 10% glycerol, 1 mM dithiothreitol (DTT), 23 mM AEBSF, 100 mM EDTA, 2 mM Bestatin, 0.3 mM E-64, 0.3 mM pepstatin A). The cells were sonicated and centrifuged at 100 000 g for 1 h. The cleared lysate was incubated with 0.5 ml of glutathione-Sepharose beads at 4degreesC for 12 h. After exhaustive washing, the retained proteins were eluted from the beads with 0.1 ml of buffer (50 mM Tris-HCl, pH 7.6, 10% glycerol) containing 20 mM glutathione. All of the purification steps were carried out at 4degreesC.
###end p 20
###begin title 21
Pre-tRNA synthesis
###end title 21
###begin p 22
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c22">22</xref>
###xml 216 218 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
The pre-tRNAsArg R-11TUUU and R-6L6TUUU were synthesized with T7 RNA polymerase (Takara Shuzo) from the synthetic DNA templates (22). The transcription reactions were carried out in the presence or absence of [alpha-32P]UTP (Amersham Pharmacia Biotech) under the conditions recommended by the manufacturer (Takara Shuzo), and the transcribed pre-tRNAs were gel-purified.
###end p 22
###begin p 23
The unlabeled pre-tRNA transcript R-6L6TUUU was subsequently labeled with fluorescein according to the manufacturer's protocol (Amersham Pharmacia Biotech). Briefly, after the removal of the 5' phosphates of the transcript with bacterial alkaline phosphatase (Takara Shuzo), the transcript was phosphorylated with T4 polynucleotide kinase (Takara Shuzo) and ATPgammaS. Then a single fluorescein moiety was appended onto the 5'-phosphorothioate site. The resulting fluorescein-labeled R-6L6TUUU was gel-purified before assays.
###end p 23
###begin title 24
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro tRNA 3' processing assay
###end title 24
###begin p 25
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 224 225 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The 3' processing reactions for 32P-labeled or fluorescein-labeled pre-tRNA (0.1 pmol) were performed with 3' tRNases of various origins in a mixture (10 microl) containing 10 mM Tris-HCl (pH 7.5), 1.5 mM DTT and 3.2 mM MgCl2 at 37degreesC for 10 min. After resolution of the reaction products on a 10% polyacrylamide-8 M urea gel, the gel was analyzed with a Typhoon 9210 (Amersham Pharmacia Biotech).
###end p 25
###begin title 26
RNA sequencing
###end title 26
###begin p 27
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 364 366 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 526 528 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c23">23</xref>
###xml 61 64 <span type="species:ncbi:9823">pig</span>
The unlabeled pre-tRNAArg R-11TUUU (2 pmol) was reacted with pig liver 3' tRNase (20 ng), ELAC2 (50 ng), YKR079C (50 ng) or ELAC1 (50 ng) under the standard assay conditions at 37degreesC for 10 min, extracted with phenol/chloroform, and precipitated with ethanol. The reaction products dissolved in water were 3'-end-labeled with T4 ligase (Takara Shuzo) and [5'-32P]pCp at 4degreesC for 10 h. The 5' cleavage products were gel-purified, and their 3'-terminal sequences were determined by the chemical RNA sequencing method (23). The gel was analyzed with the Typhoon 9210.
###end p 27
###begin title 28
RESULTS
###end title 28
###begin title 29
###xml 43 46 <span type="species:ncbi:9823">pig</span>
Microsequencing of 3' tRNase purified from pig liver
###end title 29
###begin p 30
###xml 91 93 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c10">10</xref>
###xml 246 247 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f1">1</xref>
###xml 795 800 747 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 984 985 936 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f1">1</xref>
###xml 1153 1154 1105 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f1">1</xref>
###xml 28 31 <span type="species:ncbi:9823">pig</span>
###xml 167 170 <span type="species:ncbi:9823">pig</span>
###xml 841 846 <span type="species:ncbi:9606">human</span>
###xml 1022 1027 <span type="species:ncbi:9606">human</span>
###xml 1080 1083 <span type="species:ncbi:9823">pig</span>
We previously reported that pig 3' tRNase appeared to be a protein of approximately45 kDa (10), but further enzyme purification indicated that an apparent mass of the pig liver enzyme is approximately85 kDa on an SDS-10% polyacrylamide gel (Fig. 1A). Although we were not able to identify the approximately45 kDa protein, it could have been a proteolytic cleavage product of the approximately85 kDa protein. To determine an amino acid sequence of this further purified protein, we subjected the protein in an excised gel strip to trypsin digestion and analyzed resulting peptides with a mass spectrometer. Four internal peptide sequences, AEFLLLNHFSQR, LPLFSPDFNEK, VGLAFDHMK and ALFAGDLEEMEER, were derived and searched using BLAST against GenBank. The search suggested that the protein is the ELAC2 gene product based on the fact that the human ELAC2 amino acid sequence includes all these peptide sequences with a few amino acid mismatches probably due to species difference (Fig. 1B). The calculated molecular mass of human ELAC2 is 92 kDa, which is comparable to that of the pig enzyme estimated by the SDS-polyacrylamide gel electrophoresis (Fig. 1A).
###end p 30
###begin title 31
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ELAC2 has the 3'-tRNase activity
###end title 31
###begin p 32
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 573 574 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 708 714 684 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 739 747 715 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 832 835 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 883 885 855 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 903 911 875 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 957 958 929 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 1094 1097 1066 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 1150 1151 1122 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 1207 1213 1179 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 1292 1293 1264 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 1298 1299 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 1342 1348 1314 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 146 151 <span type="species:ncbi:9606">human</span>
###xml 193 199 <span type="species:ncbi:562">E.coli</span>
###xml 300 306 <span type="species:ncbi:562">E.coli</span>
###xml 692 697 <span type="species:ncbi:9606">human</span>
###xml 708 714 <span type="species:ncbi:562">E.coli</span>
###xml 818 823 <span type="species:ncbi:9606">human</span>
###xml 1120 1123 <span type="species:ncbi:9823">pig</span>
###xml 1207 1213 <span type="species:ncbi:562">E.coli</span>
###xml 1342 1348 <span type="species:ncbi:562">E.coli</span>
To confirm that the ELAC2 product really has the 3'-tRNase activity, the complete protein coding region of an ELAC2 cDNA was PCR-amplified from a human testis cDNA library, and cloned into the E.coli expression vector pTYB11. The ELAC2 product was over-expressed as an intein-containing precursor in E.coli, and purified with chitin beads by removing its intein portion. The protein sample was checked for purity by SDS-polyacrylamide gel electrophoresis. The protein profile showed two protein bands, one of approximately60 kDa and the other of approximately100 kDa (Fig. 2). We analyzed both proteins with a mass spectrometer, and elucidated that the large and small proteins correspond to human ELAC2 and E.coli GroEL, respectively. An in vitro tRNA 3' processing assay was performed with the recombinant ELAC2 and human pre-tRNAArg R-11TUUU synthesized in the presence of [alpha-32P]UTP by using an in vitro T7 RNA polymerase transcription system (Fig. 3A), and the reaction products were separated on a 10% polyacrylamide-8 M urea gel. As expected, this protein was able to cleave pre-tRNAArg at a specific site as pig liver 3' tRNase was (Fig. 3B). A control reaction with the protein sample from the E.coli cells transformed with the vector pTYB11 generated no cleavage products (Figs 2 and 3B). We also examined commercially obtained E.coli GroEL for the 3'-tRNase activity, and confirmed that the protein has no such activity (data not shown).
###end p 32
###begin p 33
###xml 70 73 70 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c24">24</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f4">4</xref>
###xml 463 465 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c11">11</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 440 443 <span type="species:ncbi:9823">pig</span>
To determine the exact cleavage site, we incubated cold human pre-tRNAArg with the recombinant ELAC2, gel-purified the 5' cleavage product and 3'-end-labeled it with [5'-32P]pCp. Subsequently, the 32P-end-labeled product was subjected to chemical RNA sequencing (24). Figure 4 shows that the 3' sequence reads 'GCUCGGUCGGem leader (3' to 5')', indicating that the cleavage occurs after the discriminator nucleotide G as the cleavage by the pig liver enzyme does (11).
###end p 33
###begin title 34
###xml 22 27 <span type="species:ncbi:4932">yeast</span>
Identification of the yeast 3'-tRNase gene
###end title 34
###begin p 35
###xml 94 106 94 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S.cerevisiae</italic>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 335 342 335 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 416 423 416 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 707 708 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 94 106 <span type="species:ncbi:4932">S.cerevisiae</span>
###xml 444 450 <span type="species:ncbi:562">E.coli</span>
###xml 550 556 <span type="species:ncbi:562">E.coli</span>
BLAST searches of the ELAC2 amino acid sequence against GenBank revealed a single ortholog in S.cerevisiae (YKR079C) (1). ELAC2 and YKR079C share 21% identical residues and show 49% sequence similarity. To corroborate that the biological function of ELAC2 is to remove 3' trailers endoribonucleolytically from pre-tRNAs, we tested the YKR079C product for 3'-tRNase activity. A PCR-amplified protein coding region of YKR079C was cloned into the E.coli expression plasmid pGEX-4T-3, and a glutathione-S-transferase (GST)-fused protein was expressed in E.coli and purified with glutathione beads. The GST-YKR079C fusion protein appeared as a band of approximately130 kDa on an SDS-10% polyacrylamide gel (Fig. 2). The size is consistent with the calculated molecular mass of 123 kDa, which consists of 26 kDa of GST and 97 kDa of YKR079C. The identity of the protein was confirmed by LC/MS/MS analysis.
###end p 35
###begin p 36
###xml 77 80 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 325 326 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 331 332 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 383 386 371 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 454 460 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 671 672 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f4">4</xref>
###xml 708 715 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 799 804 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 454 460 <span type="species:ncbi:562">E.coli</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
###xml 727 732 <span type="species:ncbi:4932">yeast</span>
The purified GST-YKR079C fusion protein was incubated with the human pre-tRNAArg R-11TUUU under the standard conditions. As shown for human ELAC2, the two species of cleavage products were generated by the fusion protein, while the cleavage was not observed in the presence of the approximately27 kDa GST protein alone (Figs 2 and 3B). This result shows that the cleavage of pre-tRNAArg is mediated directly by YKR079C and not by GST or by contaminating E.coli proteins. The 3'-terminal sequence of the long cleavage product was determined as above, and the obtained sequence indicated that the cleavage occurs after the discriminator as in the case of human ELAC2 (Fig. 4). Therefore, we concluded that the YKR079C product is yeast 3' tRNase. Taken together, these results clearly demonstrate that ELAC2 indeed encodes tRNA 3' processing endoribonuclease.
###end p 36
###begin title 37
The C-terminal half of ELAC2 is essential for the 3'-tRNase activity
###end title 37
###begin p 38
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 783 784 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 901 907 869 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 937 943 905 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 1124 1127 1072 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 1169 1170 1113 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 901 907 <span type="species:ncbi:562">E.coli</span>
###xml 937 943 <span type="species:ncbi:562">E.coli</span>
The multiple protein alignment of ELAC2 orthologs revealed that the C-terminal half regions have much higher similarity than the N-terminal half regions (1). Thus, we assumed that the essential domains including the catalytic domain should exist in the C-terminal half of 3' tRNase. To test this possibility, we constructed two pTYB11 expression plasmids lacking either N-terminal (residues 1-481) or C-terminal (residues 481-826) half-coding region, expressed and purified half proteins as described for the full-length ELAC2. The LC/MS/MS analysis showed that the recombinant C-terminal half (ELAC2-DeltaN) and N-terminal half (ELAC2-DeltaC) 3' tRNases had apparent molecular weights of approximately53 and approximately38 kDa, respectively, on an SDS-10% polyacrylamide gel (Fig. 2). Consistently, the calculated masses were 54 and 38 kDa, respectively. Both protein samples were contaminated with E.coli GroEL, and another unrelated E.coli protein of approximately50 kDa, 2-oxoglutarate dehydrogenase, was detected in the ELAC2-DeltaN sample. In the tRNA 3' processing assay, ELAC2-DeltaN was able to cleave the pre-tRNAArg, while ELAC2-DeltaC was not at all (Fig. 3B). These results suggest that the C-terminal half of 3' tRNase is essential for its activity.
###end p 38
###begin title 39
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ELAC1 has also the tRNA 3' processing activity
###end title 39
###begin p 40
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 433 434 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 532 533 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f2">2</xref>
###xml 859 862 843 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 890 891 874 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f3">3</xref>
###xml 897 898 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f4">4</xref>
###xml 987 992 971 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
Interestingly, in the human genome exists a gene, ELAC1, which is very similar to, but about half the size of ELAC2 (1), and seems to correspond to the C-terminal half of 3' tRNase from ELAC2. To examine whether ELAC1 has also the tRNA 3' processing activity as ELAC2-DeltaN, we cloned a human cDNA encoding ELAC1 into the plasmid pGEX-4T-3, and expressed and purified the GST-ELAC1 fusion protein as described for GST-YKR079C (Fig. 2). On an SDS-10% polyacrylamide gel, GST-ELAC1 appeared as a protein of approximately70 kDa (Fig. 2), which is consistent with the calculated molecular mass of 66 kDa composed of 26 kDa from GST and 40 kDa from ELAC1. The protein identity was confirmed by LC/MS/MS analysis. From the 3'-tRNase assay for GST- ELAC1 and the RNA sequencing of the cleavage product, we demonstrated that the ELAC1 enzyme can also cleave pre-tRNAArg at the expected site (Figs 3B and 4). This result emphasizes the importance of the C-terminal half domain of 3' tRNase from ELAC2.
###end p 40
###begin title 41
###xml 8 11 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
Pre-tRNAArg containing a 5' leader is also a good substrate for ELAC2 and ELAC1
###end title 41
###begin p 42
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 290 298 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f5">5</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f5">5</xref>
###xml 697 698 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f5">5</xref>
###xml 8 11 <span type="species:ncbi:9823">pig</span>
###xml 176 181 <span type="species:ncbi:9606">human</span>
###xml 251 256 <span type="species:ncbi:9606">human</span>
###xml 437 442 <span type="species:ncbi:9606">human</span>
###xml 501 504 <span type="species:ncbi:9823">pig</span>
Because pig liver 3' tRNase can remove 3' trailers efficiently even from pre-tRNAs containing 5' leaders if the length of leaders is smaller than 9 nt, we examined whether the human pre-tRNAArg containing a 5' leader R-6L6TUUU is also a substrate for human ELAC2. R-6L6TUUU was synthesized in vitro with T7 RNA polymerase, and subsequently 5'-end-labeled with fluorescein (Fig. 5A). In the 3'-tRNase assay under the standard conditions, human recombinant ELAC2 cleaved R-6L6TUUU as efficiently as the pig liver enzyme (Fig. 5B). We also examined the ELAC2-DeltaC, ELAC2-DeltaN, YKR079C and ELAC1 enzymes, and showed that these enzymes can cleave R-6L6TUUU with the exception of ELAC2-DeltaC (Fig. 5B).
###end p 42
###begin title 43
tRNA 3' processing activities of enzyme variants associated with the occurrence of prostate cancer
###end title 43
###begin p 44
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c3">3</xref>
###xml 565 573 565 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1641insG</sup>
###xml 604 613 604 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu</sup>
###xml 620 629 620 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ala541Thr</sup>
###xml 639 648 639 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg781His</sup>
###xml 679 698 679 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu/Ala541Thr</sup>
###xml 705 724 705 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ala541Thr/Arg781His</sup>
###xml 734 754 734 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg781His/ Ser217Leu</sup>
###xml 785 814 785 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ser217Leu/Ala541Thr/Arg781His</sup>
###xml 890 896 890 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 1204 1205 1204 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkg337f6">6</xref>
###xml 890 896 <span type="species:ncbi:562">E.coli</span>
It has been reported that two mutations in ELAC2, an insertion/frameshift (1641 ins G) and a missense change (Arg781His), segregate with prostate cancer in two pedigrees (1). The frameshift mutation results in premature termination after the miscoding of 67 residues. In addition, two common missense changes, Ser217Leu and Ala541Thr, seem to be associated with the occurrence of prostate cancer (1-3). In order to investigate the effects of these mutations on the 3'-tRNase activity, we constructed eight expression plasmids which can produce one frameshift (ELAC21641insG), three single missense (ELAC2Ser217Leu, ELAC2Ala541Thr and ELAC2Arg781His), three double missense (ELAC2Ser217Leu/Ala541Thr, ELAC2Ala541Thr/Arg781His and ELAC2Arg781His/ Ser217Leu) or one triple missense (ELAC2Ser217Leu/Ala541Thr/Arg781His) variant enzyme, based upon pTYB11/ELAC2. These variants were expressed in E.coli, purified and assayed for 3'-tRNase activity. Seven ELAC2 variants which contain one to three amino acid substitutions showed efficient 3'-tRNase activities, while one truncated variant, which lacked a C-terminal half region, had no activity, emphasizing again the importance of the C-terminal domain (Fig. 6).
###end p 44
###begin title 45
DISCUSSION
###end title 45
###begin p 46
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 1088 1091 1088 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 1302 1307 1302 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 27 30 <span type="species:ncbi:9823">pig</span>
###xml 156 161 <span type="species:ncbi:9606">human</span>
###xml 263 268 <span type="species:ncbi:9606">human</span>
###xml 328 334 <span type="species:ncbi:562">E.coli</span>
###xml 838 843 <span type="species:ncbi:4932">yeast</span>
###xml 917 922 <span type="species:ncbi:4932">yeast</span>
###xml 1244 1247 <span type="species:ncbi:9823">pig</span>
We purified 3' tRNase from pig liver and determined its partial sequences by mass spectrometry. The BLAST search of them against GenBank suggested that the human ELAC2 gene is the gene that encodes 3' tRNase. To demonstrate this directly, we cloned the cDNA from human testis into the expression plasmid pTYB11, expressed it in E.coli and purified the ELAC2 product. The obtained ELAC2 sample clearly showed the 3'-tRNase activity, although it was contaminated with the bacterial GroEL. The possibility that GroEL has the 3'-tRNase activity was excluded by the experiment using the purchased pure GroEL. Another possibility that the observed activity is due to a trace amount of other contaminated bacterial proteins was also ruled out by the assay using the sample from mock transformed bacteria. Furthermore, we confirmed that a single yeast ortholog, YKR079C, has the 3'-tRNase activity by testing the recombinant yeast enzyme obtained through a different expression system with the vector pGEX-4T-3. We also showed that both recombinant enzymes, ELAC2 and YKR079C, can cleave pre-tRNAArg precisely after the discriminator nucleotide and that they can process not only pre-tRNA without a 5' leader but also pre-tRNA with the leader like the pig liver 3' tRNase. Therefore, we conclude that the gene ELAC2 indeed encodes 3' tRNase. In addition, our data suggest that no other protein factors and no eukaryote-specific modifications are essential for the 3'-tRNase activity of ELAC2.
###end p 46
###begin p 47
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c25">25</xref>
###xml 862 864 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c26">26</xref>
###xml 888 895 884 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 1206 1213 1202 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 1357 1364 1353 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 56 61 <span type="species:ncbi:4932">yeast</span>
###xml 97 102 <span type="species:ncbi:4932">yeast</span>
###xml 230 235 <span type="species:ncbi:4932">yeast</span>
###xml 779 784 <span type="species:ncbi:4932">yeast</span>
###xml 1321 1326 <span type="species:ncbi:4932">yeast</span>
The YKR079C gene has been shown to be indispensable for yeast viability (1), suggesting that the yeast genome may have only one gene that encodes an enzyme responsible for correctly removing 3' trailers from pre-tRNAs. Although a yeast 3' tRNase with a molecular weight of 45/60 kDa has been identified, which can catalyze precise cleavage of a pre-tRNA at the discriminator site (25), the gene of this enzyme was unidentified. It is possible that the 45/60 kDa proteins detected on the polyacrylamide gel are degradation products of the 97 kDa intact YKR079C protein. Even these about half-size degradation products, if they contain the majority of the C-terminal domain, should show the 3'-tRNase activity like ELAC2-DeltaN. Although several studies suggested the existence in yeast of another pathway to remove 3' trailers by utilizing only exoribonucleases (26), the necessity of the YKR079C gene may argue against such pathways. Even in the situations where exoribonucleases can be involved in the pre-tRNA 3' processing, the final cut to generate the discriminator termini for the CCA-adding enzyme may be carried out by 3' tRNase. An alternative interpretation is also possible. The reason that the YKR079C gene is indispensable may be because the gene has another unknown essential function. Several unidentified yeast genes that are not related to YKR079C might also encode 3' processing endoribonucleases.
###end p 47
###begin p 48
###xml 145 165 145 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arabidopsis thaliana</italic>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c27">27</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c7">7</xref>
###xml 764 765 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c7">7</xref>
###xml 766 768 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c28">28</xref>
###xml 914 915 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 1121 1123 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c29">29</xref>
###xml 1183 1184 1176 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 145 165 <span type="species:ncbi:3702">Arabidopsis thaliana</span>
###xml 300 305 <span type="species:ncbi:9606">human</span>
###xml 354 359 <span type="species:ncbi:9606">Human</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 1170 1175 <span type="species:ncbi:9606">human</span>
We showed that human ELAC1, which is very similar to the C-terminal half domain of human ELAC2, has the 3'-tRNase activity. An ELAC1 ortholog of Arabidopsis thaliana has been also reported to show 3'-tRNase activity (27). These results are consistent with the observation that the C-terminal half of human ELAC2 is sufficient for the 3'-tRNase activity. Human ELAC2, human ELAC1 and their orthologs contain the histidine motif hhh[S/T]HXHXDHXXG (where h can be any bulky hydrophobic residue), which is highly conserved among them and forms a potential divalent metal ion binding site (1,7). It has been demonstrated experimentally that several histidine motifs are crucial for catalysis by enzymes such as beta-lactamases and cyclic nucleotide phosphodiesterases (7,28). Curiously, ELAC2-DeltaC did not show the 3'-tRNase activity at all, even though the N-terminal half sequence is similar to the C-terminal one (1). This may be because of the lack of an intact histidine motif. The above consideration implies that the histidine motif is important for the 3'-tRNase catalytic activity. In contrast, the Walker A motif (29) that exists in the N-terminal half region of human ELAC2 (1) is not essential for the activity. This ATP/GTP-binding motif may be involved in regulation of the catalysis by means of ATP or GTP.
###end p 48
###begin p 49
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 104 126 104 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans</italic>
###xml 131 143 131 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S.cerevisiae</italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 630 632 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c30">30</xref>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 104 126 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 131 143 <span type="species:ncbi:4932">S.cerevisiae</span>
###xml 449 454 <span type="species:ncbi:9606">human</span>
###xml 536 541 <span type="species:ncbi:9606">human</span>
BLAST searches revealed that the human genome contains both ELAC1 and ELAC2 genes, while the genomes of Caenorhabditis elegans and S.cerevisiae have only ELAC2 (1). This raises an interesting question whether the two distinct 3' tRNases from ELAC1 and ELAC2 play differential roles in tRNA processing in the cells. It is possible that one is for nuclear tRNA processing, and that the other is for mitochondrial use. Although the iPSORT analysis for human ELAC2 predicted a mitochondrial localization, it has been reported recently that human ELAC2 exists both in cytoplasm and nuclei and interacts with the gamma-tubulin complex (30). The ELAC2/gamma-tubulin interaction suggests an additional function of ELAC2 such as cell cycle regulation.
###end p 49
###begin p 50
###xml 18 26 18 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1641insG</sup>
###xml 1442 1447 1442 1447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 1472 1473 1472 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c1">1</xref>
###xml 1474 1475 1474 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c6">6</xref>
###xml 1954 1959 1954 1959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 329 334 <span type="species:ncbi:9606">human</span>
As expected, ELAC21641insG, which lacks most of the C-terminal domain, did not show the enzymatic activity at all. Thus, 1641insG homozygotes must be lethal, unless the cells have another equivalent backup enzyme. Our data suggests that ELAC1 might be such an enzyme. Alternatively, some compensatory frameshift mechanism of the human translation system might generate an active enzyme. How could 1641insG heterozygotes confer increased risk of prostate cancer? The aberrant enzyme could interact with some unidentified regulatory factors, sequester them and interfere with the intact enzyme's function, resulting in perturbation of the network of cellular gene regulation. In contrast, from the present assays, we did not observe meaningful differences in the 3'-tRNase activity between the wild-type ELAC2 and three single missense, three double missense and one triple missense variant enzymes. It is possible, however, that some differences could be detected when different pre-tRNA species are tested or kinetic parameters are measured. In any case, these missense variants all had sufficiently strong 3'-tRNase activities, although the substitution of Ser217 with the bulky hydrophobic residue Leu could affect the protein structure, and Ala541 which lies at the amino border of the histidine motif could be important for the enzymatic activity. Whether there are causalities between prostate cancer and the above missense mutations in ELAC2 is still controversial (1-6). From our results, it seems that the causalities could be fairly complicated, if they exist. The variant enzymes could differentially interact with some unknown regulatory proteins, or could be degraded more easily than the wild type, resulting in perturbation of cellular normal metabolism. Although it would not be straightforward to elucidate how such mutations could lead the cells to a malignant state, the present study in which we found out the cellular function of the ELAC2 product would be a great leap.
###end p 50
###begin title 51
Figures and Tables
###end title 51
###begin p 52
###xml 56 57 56 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c10">10</xref>
###xml 288 289 288 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 40 43 <span type="species:ncbi:9823">pig</span>
###xml 104 107 <span type="species:ncbi:9823">pig</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
 Purification and partial sequencing of pig 3' tRNase. (A) The enzyme was intensively fractionated from pig liver basically as described before (10), and further purified by glycerol gradient ultracentrifugation. The final active fraction was separated on an SDS-10% polyacrylamide gel. (B) The four sequences derived from mass spectrometric analysis of the approximately85 kDa band are aligned with a C-terminal portion of the human ELAC2 sequence.
###end p 52
###begin p 53
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC2</italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 279 286 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YKR079C</italic>
###xml 291 296 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELAC1</italic>
###xml 333 339 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 488 494 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 957 963 945 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 1047 1053 1019 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E.coli</italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 119 125 <span type="species:ncbi:562">E.coli</span>
###xml 333 339 <span type="species:ncbi:562">E.coli</span>
###xml 488 494 <span type="species:ncbi:562">E.coli</span>
###xml 957 963 <span type="species:ncbi:562">E.coli</span>
###xml 1047 1053 <span type="species:ncbi:562">E.coli</span>
 Recombinant protein profiles. The full, 5'-half and 3'-half coding regions of a human ELAC2 cDNA were cloned into the E.coli expression vector pTYB11 to produce the recombinant proteins ELAC2, ELAC2-DeltaC (residues 1-480) and ELAC2-DeltaN (residues 482-826), respectively. The YKR079C and ELAC1 coding regions were cloned into the E.coli expression vector pGEX-4T-3 to generate the recombinant proteins YKR079C and ELAC1, respectively. These recombinant proteins were over-expressed in E.coli, and purified with chitin or glutathione beads by a batch method. The vectors pTYB11 and pGEX-4T-3 were also used for mock transformations. The purified proteins (1 microg) were analyzed on an SDS-10% polyacrylamide gel, and stained with Coomassie brilliant blue R-250. By mass spectrometric analysis, we confirmed that each protein band designated by an arrowhead corresponds to each recombinant protein and that a band designated by an asterisk corresponds to E.coli GroEL. An approximately50 kDa protein in the ELAC2-DeltaN sample was identified as E.coli 2-oxoglutarate dehydrogenase.
###end p 53
###begin p 54
###xml 57 65 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 96 97 96 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 202 203 202 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 451 453 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c13">13</xref>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 281 284 <span type="species:ncbi:9823">pig</span>
###xml 351 356 <span type="species:ncbi:9606">human</span>
 Tests of various ELAC2-related recombinant proteins for in vitro tRNA 3' processing activity. (A) A secondary structure of human pre-tRNAArg R-11TUUU. An arrow denotes the cleavage site by 3' tRNase. (B) The in vitro tRNA 3' processing assays. Each recombinant protein (50 ng) or pig liver 3' tRNase (20 ng) was incubated with uniformly 32P- labeled human pre-tRNAArg R-11TUUU (0.1 pmol) at 37degreesC for 10 min under the standard assay conditions (13). The cleavage reactions were analyzed on a 10% polyacrylamide-8 M urea gel.
###end p 54
###begin p 55
###xml 147 155 147 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 202 204 202 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c24">24</xref>
 Determination of the exact cleavage site by recombinant 3' tRNases, ELAC2, YKR079C and ELAC1. The unlabeled 5' cleavage products generated in the in vitro 3'-tRNase assays were 3'-end-labeled with [5'-32P]pCp and T4 RNA ligase, gel-purified and subjected to chemical RNA sequencing (24). The sequencing reactions were analyzed on a 20% polyacrylamide-8 M urea gel. The 3'-terminal nucleotide G corresponds to the discriminator.
###end p 55
###begin p 56
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arg</sup>
###xml 188 189 188 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 195 203 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 408 410 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c13">13</xref>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 258 261 <span type="species:ncbi:9823">pig</span>
 Assays of ELAC2-related recombinant proteins for the 3'-tRNase activity. (A) A secondary structure of the human pre-tRNAArg R-6L6TUUU. An arrow indicates the cleavage site by 3' tRNase. (B) The in vitro 3'-tRNase assays. Each recombinant protein (50 ng) or pig liver 3' tRNase (20 ng) was incubated with fluorescein-labeled R-6L6TUUU (0.1 pmol) at 37degreesC for 10 min under the standard assay conditions (13). The cleavage reactions were analyzed on a 10% polyacrylamide-8 M urea gel.
###end p 56
###begin p 57
###xml 93 94 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 321 322 313 314 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 501 503 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkg337c13">13</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
 3'-tRNase activities of enzyme variants associated with the occurrence of prostate cancer. (A) Positions of the mutations in human ELAC2. Regions of the Walker A motif and the histidine motif are denoted by shaded rectangles. The regions corresponding to ELAC2-DeltaC and ELAC2-DeltaN are also indicated by thick bars. (B) The 3'-tRNase assays were performed with each variant enzyme (25 and 50 ng) and fluorescein-labeled R-6L6TUUU (0.1 pmol) at 37degreesC for 10 min under the standard conditions (13). The cleavage reactions were analyzed on a 10% polyacrylamide-8 M urea gel. Values of percent cleavage for low and high enzyme dosages were represented by open and filled bars, respectively. Data are the mean +/- SD of three independent experiments.
###end p 57
###begin title 58
ACKNOWLEDGEMENTS
###end title 58
###begin p 59
We thank M. Takeda and members of the NUPALS Undergraduate Molecular Biology Club for technical assistance.
###end p 59
###begin title 60
REFERENCES
###end title 60

